Open AccessHigh-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study.
Author(s) -
M Britton,
C. Helmers,
Kristin Samuelsson,
Magnus von Arbin,
Anders Carlsson,
Ulf dé Fairé,
Claes M. Gustafsson,
G Kolmodin,
S. Landin,
A Swahn,
Paul Wesson,
M Ekeroth,
L.-G Hjeme,
Kerry C. Mian,
E Ersmark,
Anders Hedberg
Publication year - 1987
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/01.str.18.2.325
Subject(s) - medicine , stroke (engine) , placebo , cerebral infarction , myocardial infarction , infarction , cardiology , anesthesia , clinical trial , secondary prevention , surgery , ischemia , pathology , mechanical engineering , alternative medicine , engineering
Within 3 weeks of the event, 505 patients with cerebral infarction, minor or major stroke, were randomly assigned to treatment with acetylsalicylic acid (ASA) 1.5 g/day or placebo in a double-blind clinical trial with a follow-up of 2 years in all patients. Primary events were considered to be recurrent stroke or death; secondary events, myocardial infarction and transient ischemic attack. There was no difference in stroke recurrence rate in the ASA and placebo groups (12 and 13%, respectively), nor was there any significant difference in the rate of recurrent stroke or death, first event counted (23% in the ASA and 22% in the placebo group). The risk of transient ischemic attack and myocardial infarction was not reduced in the ASA group. In the present study there was no prophylactic effect of high-dose ASA after cerebral infarction. A compilation of the major trials of ASA after transient ischemic attack and cerebral infarction is presented.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom